预激方案HAG及CAG治疗老年初治急性髓性白血病的对比研究

Clinical Comparison Study of Priming Induction Regimen of HAG and CAG in the Treatment for Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

目的:评价含粒细胞集落刺激因子(granulocyte colony-stimulating-factor,G-CSF)的预激HAG及CAG方案治疗老年初治急性髓性白血病(AML)的疗效及不良反应,并对两个方案的疗效及不良反应进行比较。方法:65例老年初治AML分为HAG预激治疗组及CAG预激方案治疗组,31例患者予以HAG预激方案治疗,34例患者予以预激方案CAG方案治疗,所有患者在第1疗程后间歇14d左右进行第2个疗程。结果:HAG预激方案治疗组的完全缓解率为74.2%,总有效率为83.8%;CAG预激治疗组完全缓解(CR)率为67.6%,总有效率达为82.4%。两治疗组的血液系统不良反应及非血液系统毒性不良反应比较无显著性差异。结论:HAG预激方案化疗强度温和、敏感性好、CR率及有效率高、毒副作用小;与CAG预激治疗比较,HAG预激方案可以取的相似的疗效及较少的不良反应,在老年初治AML患者值得推荐应用。

Objective： To evaluate and compare the clinical efficacy and toxicity of priming induction regimens of HAG and CAG in the treatment for newly diagnosed acute myeloid leukemia in elderly patients. Methods： Sixty-five patients were divided into two groups： thirty-one elderly patients with AML were treated with priming induction regimen CAG, and thirty-four elderly patients with AML were treated with priming induction regimen CAG. All patients have an intermission about two weeks for the second course of chemotherapy. Results： The complete remission rate in patients with the priming induction regimen HAG was 74.2%, the total efficacy rate was 83,8%, and the priming induction regimen CAG with complete remission rate 67.6%, the total efficacy rate was 82.4%. The hematological and non-hematological side effects in the HAG and CAG groups had no significantly differences. Conclusions： The priming induction regimens of HAG and CAG have similarily complete remission rate and effective rate, less side effects, mildly chemotherapy intensity and are more sensitive to chemotherapeutic drugs. It should be recommended for use in newly diagnosed elderly acute myeloid leukemia patients.